Beta
Angiotensin receptor blockers (e.g. losartan, valsartan, irbesartan)
medication Under reviewAngiotensin receptor blockers (ARBs) such as losartan, valsartan, and irbesartan are prescription medications that selectively block the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding to AT1 receptors in blood vessels and the adrenal glands, they reduce vasoconstriction and aldosterone release, leading to lower blood pressure and reduced mechanical stress on the cardiovascular system. Unlike ACE inhibitors, ARBs do not interfere with bradykinin breakdown, which generally results in fewer cough-related side effects. In healthy humans, ARBs primarily influence the renin–angiotensin–aldosterone system without causing clinically significant blood pressure reductions at standard single doses, but they clearly blunt the pressor response to exogenous angiotensin II. This allows researchers to characterize receptor occupancy, duration of antagonism, and comparative potency among different ARBs under controlled conditions. While their main clinical applications are in hypertension, heart failure, and diabetic nephropathy, mechanistic studies in normotensive volunteers help to clarify dosing requirements and receptor-binding dynamics that underpin these therapeutic uses. Losartan is the prototypical ARB and is converted to an active metabolite that mediates most of its receptor-blocking effects. Valsartan and irbesartan are more lipophilic and show differences in receptor affinity and dissociation kinetics, which translate into varying durations and intensities of AT1 blockade. These pharmacologic distinctions can be demonstrated in healthy subjects using angiotensin II challenge tests and radioreceptor assays, and they are relevant when selecting agents and doses to achieve sustained 24‑hour blood pressure control in clinical practice.
Research summary
Human studies in healthy volunteers consistently show that losartan, valsartan, and irbesartan produce dose‑dependent angiotensin II receptor blockade, measurable as attenuation of blood pressure responses to angiotensin II and increased AT1 receptor occupancy. Comparative trials demonstrate that irbesartan tends to provide more intense and longer‑lasting AT1 antagonism than losartan and valsartan at commonly used single and repeated doses, while higher doses of valsartan can achieve blockade comparable to recommended doses of irbesartan. These mechanistic insights in normotensive subjects clarify that apparent differences between agents are largely driven by dose and pharmacokinetic properties. Clinical efficacy data come mainly from patients with hypertension rather than healthy volunteers, but they support the relevance of these mechanistic findings. Valsartan at 160–320 mg has been shown to lower blood pressure more than losartan 100 mg and similarly to other ARBs, and comparative class reviews note differences in receptor affinity and potency that may translate into variations in cardiovascular outcomes across agents. Overall, the research consensus is that ARBs are effective, generally well tolerated cardiovascular drugs whose receptor-binding characteristics, duration of action, and clinical effects differ modestly between individual molecules.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Angiotensin receptor blockers (e.g. losartan, valsartan, irbesartan) to your stack to report effects
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Mourad JJ, Waeber B, Zanchetti A, et al.
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Bourlier D, Azizi M, Guyene TT, Menard J
Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Azizi M, Chatellier G, Guyene TT, Menard J
Valsartan Versus Other Angiotensin II Receptor Blockers in the Treatment of Hypertension: A Systematic Review
Bangalore S, Kumar S, Messerli FH
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Azizi M, Menard J, Bissery A, Guyene TT, Velazquez E
No reports yet
Be the first to report this effect and help the community.
Add Angiotensin receptor blockers (e.g. losartan, valsartan, irbesartan) to your stack to report effects
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Mourad JJ, Waeber B, Zanchetti A, et al.
Valsartan Versus Other Angiotensin II Receptor Blockers in the Treatment of Hypertension: A Systematic Review
Bangalore S, Kumar S, Messerli FH
Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Azizi M, Chatellier G, Guyene TT, Menard J
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Azizi M, Menard J, Bissery A, Guyene TT, Velazquez E
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Bourlier D, Azizi M, Guyene TT, Menard J
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Valsartan Versus Other Angiotensin II Receptor Blockers in the Treatment of Hypertension: A Systematic Review
Bangalore S, Kumar S, Messerli FH
Hypertension — elevated blood pressure requiring management
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Mourad JJ, Waeber B, Zanchetti A, et al.
Valsartan Versus Other Angiotensin II Receptor Blockers in the Treatment of Hypertension: A Systematic Review
Bangalore S, Kumar S, Messerli FH
Research (5 studies)
Valsartan Versus Other Angiotensin II Receptor Blockers in the Treatment of Hypertension: A Systematic Review
Bangalore S, Kumar S, Messerli FH
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Bourlier D, Azizi M, Guyene TT, Menard J
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Azizi M, Menard J, Bissery A, Guyene TT, Velazquez E
Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects.
Azizi M, Chatellier G, Guyene TT, Menard J
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Mourad JJ, Waeber B, Zanchetti A, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!